(secondQuint)A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071).

 Following the 96-week double-blind study period (MK0518-071)(NCT00745823), subjects may enroll in an extension study (MK0518-071-10)(NCT00745823).

 From weeks 96 to 120, subjects' treatment assignments will remain as in the base study.

 From week 120 to 240, all subjects will receive open-label raltegravir (800 mg, once daily) in combination with TRUVADA cent .

.

 A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)@highlight

A study to evaluate the safety, tolerability and efficacy of once daily Raltegravir compared to twice daily raltegravir when each is given in combination with TRUVADA cent in treatment-naive human immunodeficiency virus (HIV)-infected patients.

